Heads of HTA Agencies Group convene in Lisbon for fourth meeting
HTA Agencies Meeting Updates: It seems the Heads of HTA Agencies Group had a productive meeting in Lisbon, Portugal. They discussed key strategic topics including the confirmation of the new Vice-Chair, updates on the HTA Regulation and long-term strategic planning for the group!
Next meeting will take place in Stockholm, Sweden in May 2023.
Recent Posts
Breakthrough in cemdisiran gMG treatment Advances Regulatory Landscape
Cemdisiran gMG treatment has cleared a critical hurdle after the FDA and EMA accepted Regeneron’s regulatory submissions for review in anti-AChR antibody-positive generalized myasthenia gravis (gMG). The investigational siRNA therapy targeting complement protein C5 could become the first subcutan...
Advancements in Breast Cancer Treatment Following Trodelvy ADC Approval
The Trodelvy ADC approval by the European Commission delivers the first antibody-drug conjugate approved for first-line use in adults with unresectable or metastatic triple-negative breast cancer who are ineligible for PD-1 or PD-L1 inhibitors. This
Cemiplimab Cervical Cancer Access Navigating Treatment and Value
Cemiplimab Cervical Cancer Access has been endorsed by NICE for adults with recurrent or metastatic cervical cancer that has progressed after platinum-based chemotherapy, provided patients have not previously received immunotherapy. The final draft guidance confirms that this PD-1 inhibitor deliv...